Could early heart support protect Brain-Injured newborns?
NCT ID NCT07406477
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Some newborns with HIE, a brain injury from lack of oxygen at birth, also develop heart problems. This pilot trial tests whether starting a heart medication called dobutamine early, before heart failure signs appear, is feasible and safe. Forty babies receiving cooling therapy will be randomly assigned to early dobutamine or a placebo. The goal is to see if this approach can be reliably done and to gather initial data for a larger future study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dobutamine
What this could lead to
If this pilot succeeds, it could lead to a larger trial that may show early heart support improves outcomes for babies with HIE.
What could go wrong
This is a very small, early-phase pilot study with only 40 babies. It is designed to test feasibility, not effectiveness, so it may not lead to a proven treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC-ISCHEMIC ENCEPHALOPATHY (HIE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal Alexandra Hospital
Edmonton, Alberta, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••